Brainsway (BWAY) Stock Forecast & Price Target

BrainsWay is well positioned because its Deep TMS platform is generating expanding clinical validation and tangible commercial pull, including a multi-unit order through Inland Psychiatric Medical Group and a growing installed-base model that supports recurring, high-margin revenue. The evidence base is strengthening across multiple indications, with a 70% relative reduction in suicidal ideation over six weeks in 89 MDD patients, an 83.3% response rate and 50% remission rate in 12 patients with MDD and early-stage Alzheimer's, and an 83.5% PTSD symptom response rate in 462 real-world patients across 11 clinical sites. Combined with a new FDA clearance application for comorbid PTSD/MDD, ongoing AUD enrollment, and planned feasibility studies in dementia and Parkinson's disease, the company appears to have multiple pathways to sustained growth and broader regulatory expansion.

BrainsWay is benefiting from broader U.S. reimbursement, with over 70M covered lives now accessible under policies covering SWIFT, which should support adoption of its Deep TMS platform. However, the investment case remains fragile because the valuation depends on a 5.6x sales multiple applied to $78.5M in forward 12-month revenue, while execution risks include slower-than-projected system uptake, limited expansion into other indications, and possible long-term dilution. Its ARR-driven model and ~$62.1M in cash as of mid-2026 offer some support, but inconsistent commercial execution, pricing pressure, regulatory delays, and higher operating expenses could prevent sustainable profitability and undermine downside protection.